Barrier Dynamics and Immune Interplay in Brain Aging and Injury
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 June 2024 | Viewed by 467
Special Issue Editors
Interests: stroke; blood–brain barrier; neuroinflammation; oxidative stress; natural compounds; stem cell
Special Issues, Collections and Topics in MDPI journals
Interests: aging; neurodegeneration; immune-metabolism; blood–brain barrier; neuroinflammation
Interests: Alzheimer’s disease; neuroinflammation; B-lymphocyte; T-lymphocyte; aging; tumor
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to announce the launch of a Special Issue that focuses on the lasted advances in research concerning barrier dynamics and immune interplay in brain aging and neurovascular disorders. Aging is the most significant risk factor for numerous neurodegenerative disorders and neurovascular diseases. A hallmark of aging is the development of systemic maladaptive immune responses, both in the periphery and central nervous system (CNS). As the primary interface connecting the periphery and the CNS, the integrity of the blood–brain barrier (BBB) plays a pivotal role in CNS function. Accumulating evidence suggests that systemic immune response and barrier integrity affect brain function. In this Special Issue, we aim to provide the most recent updates on research focused on ameliorating brain dysfunction by targeting barrier dynamics and immune interplay between the periphery and the CNS, in the context of aging, neurodegenerative disorders and neurovascular diseases. We welcome both original and review articles. Manuscripts addressing the following issues are of particular interest:
- Pharmaceutical Interventions for BBB Integrity: Exploring therapies and mechanistic studies to restore BBB integrity in the context of aging, neurodegenerative, and neurovascular disorders.
- Neuroimmune Therapies: Investigating interventions to modulate brain immune responses that impact CNS function, including immune cell infiltration and neuroinflammation.
- Peripheral Immune Regulation: Pharmaceutical interventions and mechanistic studies regulating peripheral immune responses, aiming to improve BBB and brain function in aging and brain injury models.
- Adjunct Therapies: Evaluation of promising therapies and clinical studies that supplement existing treatments for neurological disorders, with a focus on those targeting immunomodulation and BBB integrity.
Dr. Hansen Chen
Dr. Congcong Wang
Dr. Xin Wang
Dr. Zongshi Qin
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- aging
- neurodegenerative and neurovascular disorders
- blood–brain barrier
- immune response
- adjunct therapy
